我們已在上線！ 進一步了解
HRMY圖示

Harmony Biosciences
HRMY

37.95 USD
-0.32
0.84%
收盤時 已更新 10月16日 下午4:00 EDT
盤前交易
盤後交易
37.95
0.00
0%
1天
-0.84%
5天
-1.02%
1個月
-10.09%
3個月
13.18%
6個月
28.99%
今年迄今
1.52%
1年
46.24%
5年
-0.21%
10年
2.54%
 

關於： Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

員工： 293

醫療保健 生物科技

新聞

正面
中性
負面
市場情緒 3個月
正面 76.7%
中性 23.3%
負面 0%
正面
Zacks Investment Research
昨天
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
Harmony Biosciences gains 27.6% in six months as Wakix sales surge and pipeline advances, with new formulations and clinical milestones offering further growth opportunities.
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth?
正面
The Motley Fool
4 天前
Why Harmony Biosciences Stock Got Mashed on Monday
This, despite the move being expected. The company's new CEO will take up the post at the beginning of next year.
Why Harmony Biosciences Stock Got Mashed on Monday
正面
Investors Business Daily
5 天前
Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit
Harmony Biosciences stock took a tumble Monday after its announced the transition of current CEO Jeffrey Dayno at the end of the year.
Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit
正面
Zacks Investment Research
10 天前
HRMY vs. CSLLY: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?
HRMY vs. CSLLY: Which Stock Is the Better Value Option?
正面
Zacks Investment Research
11 天前
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?
中性
GlobeNewsWire
16 天前
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland.
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
正面
Zacks Investment Research
上個月
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report?
中性
GlobeNewsWire
上個月
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress being held from September 5-9, in Athens, Greece.
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
中性
GlobeNewsWire
上個月
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
正面
MarketBeat
2 個月前
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
Harmony Biosciences NASDAQ: HRMY highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline
查看新聞排名
價格圖表採用Lightweight Charts™實作